SBP1 TFA

This research product features a lipid nanoparticle (LNP) formulation encapsulating oseltamivir phosphate and conjugated to Spike Binding Peptide 1 (SBP1), derived from ACE2 (aa 21-43), designed for investigating controlled long-term in vivo drug release. Additionally, SBP1 immobilized on a crosslinked polymer network has shown enhanced in vitro efficiency for capturing the SARS-CoV-2 spike glycoprotein.